J Respir Med Lung Dis | Volume 1, Issue 1 | Case Report | Open Access

Weekly Low Dose Pemetrexed for an Elderly Advanced Lung Adenocarcinoma Patient Who had Failed First-Line Chemotherapy and EGFR-TKIs: A Case Report

Lihong Wang, Zaiwen Fan^*, Rong Hu and Guangqing Zhu^*

Department of Oncology, Air Force General Hospital, China

^*Correspondance to: Zaiwen Fan 

Fulltext PDF

Abstract

Elderly advanced lung adenocarcinoma patients, especially those who failed first-line chemotherapy and EGFR-TKIs, can hardly receive conventional chemotherapy. A 71-year-old woman suffering from such situation with lung adenocarcinoma of stage IV received a total of 62 times weekly low dose pemetrexed therapy (200mg, qw) intermittently and resulted in dramatically tumor response. It is well tolerated. Weekly low dose pemetrexed might be suitable for EGFR-TKIs resistant elderly advanced lung adenocarcinoma patients.

Keywords:

Pemetrexed; Low dose; Weekly therapy; Lung adenocarcinoma

Citation:

Wang LH, Fan ZW, Hu R, Zhu GQ. Weekly Low Dose Pemetrexed for an Elderly Advanced Lung Adenocarcinoma Patient Who had Failed First-Line Chemotherapy and EGFR-TKIs: A Case Report. J Respir Med Lung Dis. 2016; 1(1): 1004.